# COLchicine On-admission to Reduce Inflammation in Acute Coronary Syndrome (COLOR-ACS)

Study · id `cardio:ct-nct05250596` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05250596](<https://clinicaltrials.gov/study/NCT05250596>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT05250596

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 182 participants.

## Technical summary

Registry record NCT05250596. Randomized; no masking; primary purpose treatment. Start 2022-02-24 (actual); primary completion 2024-02-24 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 182 participants (enrolled count; ClinicalTrials.gov record NCT05250596, source copy `cardio:ctgov-nct05250596-2024-07-16`, retrieved 2026-10-31)
- Started: 2022-02-24 (actual) (ClinicalTrials.gov record NCT05250596, source copy `cardio:ctgov-nct05250596-2024-07-16`, retrieved 2026-10-31)
- Primary completion: 2024-02-24 (actual) (ClinicalTrials.gov record NCT05250596, source copy `cardio:ctgov-nct05250596-2024-07-16`, retrieved 2026-10-31)
- Completion: 2024-05-30 (actual) (ClinicalTrials.gov record NCT05250596, source copy `cardio:ctgov-nct05250596-2024-07-16`, retrieved 2026-10-31)
- Countries: Italy (ClinicalTrials.gov record NCT05250596, source copy `cardio:ctgov-nct05250596-2024-07-16`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05250596-2024-07-16`, retrieved 2026-10-31)

## The registry's words

- Brief title: COLchicine On-admission to Reduce Inflammation in Acute Coronary Syndrome (COLOR-ACS)
- Acronym: COLOR-ACS
- Condition: Non ST Segment Elevation Acute Coronary Syndrome
- Intervention (Drug): Colchicine
- Intervention (Drug): Atorvastatin
- Lead sponsor: Azienda USL Toscana Centro
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Acute coronary syndrome (`cardio:acute-coronary-syndrome`)
- Registry intervention name matches this record: Colchicine (`cardio:colchicine`)
- Registry intervention name matches this record: Atorvastatin (`cardio:atorvastatin`)

## Provenance

Content hash: 3dd405cb988cbba9b24b29610774315c920450ec86d82dd83f660a928e19e6d0
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
